Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (ATTEMPT)

Aspirin and a Potent P2Y12 Inhibitor Versus Aspirin and Clopidogrel Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention for Complex Lesion Treatment (SMART-ATTEMPT)

This study is a prospective, open label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective percutaneous coronary intervention with drug eluting stents for complex coronary lesions.

Study Overview

• Status: Recruiting
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin

Detailed Description

Over the past several decades, dual antiplatelet therapy (DAPT) with the combination of aspirin and a P2Y12 inhibitor has become an essential treatment in patients undergoing percutaneous coronary intervention (PCI) to reduce ischemic events. Although the optimal duration of DAPT still remains controversial in patients with coronary artery disease, the recommended duration of maintenance of DAPT for patients undergoing PCI with drug-eluting stent is ≥12 months for those with acute coronary syndrome (ACS), and ≥6 months for those with stable coronary artery disease according to the current guidelines. However, individualized approach based on ischemic versus bleeding risks assessment is needed to determine the optimal duration of DAPT in various population.

Several studies reported that patients undergoing PCI for complex lesions had significantly higher rates of ischemic events than those with non-complex lesions. Moreover, prolonged DAPT of aspirin and clopidogrel more than 1 year significantly reduced the risk of cardiac ischemic events up to 44% in patients undergoing PCI for complex coronary lesions, and the current guideline recommends prolonged DAPT duration may be considered in patients undergoing complex PCI. Apart from prolonged use of DAPT, use of more potent P2Y12 inhibitor than clopidogrel may be another strategy to reduce ischemic events in patients undergoing PCI for complex coronary lesions. Prasugrel, a new thienopyridine, inhibits platelet aggregation more rapidly and potently than clopidogrel. In the TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel) study, prasugrel reduced ischemic events compared with clopidogrel in patients with acute coronary syndrome. Moreover, low dose prasugrel also reduced ischemic events without an excessive bleeding risk in Japanese population. Therefore, DAPT of aspirin and prasugrel would reduce recurrent ischemic events than DAPT of aspirin and clopidogrel in patients undergoing PCI for complex lesions, a high risk group of ischemic events, even when they do not present with myocardial infarction. So far, there have been no data on this issue.

The aim of the SMART-ATTEMPT (Aspirin and a PoTent P2Y12 inhibitor versus aspirin and clopidogrel Therapy in patients undergoing Elective percutaneous coronary intervention for coMPlex lesion Treatment) trial is to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective PCI for complex lesions.

• Study Type: Interventional
• Enrollment (Anticipated): 3500
• Phase: Phase 4

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 06351
    • Recruiting
    • Samsung Medical Center
  • Seoul, Korea, Republic of
    • Recruiting
    • Samsung Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ① Subject must be at least 19 years of age
• ② Subject who can verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure

• ③ Patients undergoing elective PCI as follows:

  1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5 mm size
  2. Chronic total occlusion (≥3 months) as target lesion
  3. PCI for unprotected left main disease (left main ostium, body, or distal bifurcation including non-true bifurcation lesions)
  4. Long coronary lesions (expected stent length ≥38 mm)
  5. Multi-vessel PCI (≥2 vessels treated at one PCI session)
  6. Multiple stent needed (≥3 stents per patient)
  7. In-stent restenosis lesion as target lesion
  8. Severely calcified lesion (encircling calcium in angiography)
  9. Ostial lesions of left anterior descending artery, left circumflex artery, or right coronary artery

Exclusion Criteria:

• ① Hemodynamic instability or cardiogenic shock
• ② Subjects with serious bleeding (Intracerebral hemorrhage, gastrointestinal bleeding, hematuria, hemoptysis, and etc.)
• ③ Previous history of intracerebral hemorrhage, transient ischemic attack, or stroke
• ④ Known hypersensitivity or contraindications to study medications (aspirin, clopidogrel, and prasugrel)
• ⑤ Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
• ⑥ Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
• ⑦ Patients presenting with biomarker positive acute coronary syndrome
• ⑧ Patients chronically taking prasugrel or ticagrelor (≥1 week)
• ⑨ Subjects ≥75 years of age or <60 kg of body weight

• ⑩ Patients taking warfarin or novel oral anticoagulants (dabigatran, rivaroxaban, edoxaban, or apixaban)

  • Eligible patients will be randomly assigned to treatment arms, stratified by participating centers, presence of diabetes mellitus, and stent types.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Prasugrel plus Aspirin arm; Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of prasugrel 60 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus prasugrel 10 mg once daily* will be given for one year. * Based on previous studies including PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI) or TRILOGY ACS (The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes), maintenance dose can be reduced to 5 mg once daily in patients with high bleeding risk or by investigator's medical judgement.	Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin; Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion; Prasugrel plus Aspirin arm; Clopidogrel plus Aspirin arm; Other Names: Prasugrel plus Aspirin or Clopidogrel plus Aspirin
Active Comparator: Clopidogrel plus Aspirin arm; Patients will receive 300 mg of aspirin before PCI unless they have previously received this antiplatelet medication. A loading dose of clopidogrel 600 mg will be given before or after PCI as soon as possible following randomization, unless they have previously received the assigned medication. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for one year.	Drug: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin; Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion; Prasugrel plus Aspirin arm; Clopidogrel plus Aspirin arm; Other Names: Prasugrel plus Aspirin or Clopidogrel plus Aspirin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major adverse cardiac events (MACE)	A composite of death, myocardial infarction, or stent thrombosis	1-year after randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All-cause death	Death by any cause	1-year after randomization
Cardiac death	Death by cardiac cause	1-year after randomization
Myocardial infarction	Myocardial infarction	1-year after randomization
Stent thrombosis	Definite or probable stent thrombosis	1-year after randomization
Target lesion revascularization	Repeat revascularization for target lesion of index PCI	1-year after randomization
Target vessel revascularization	Repeat revascularization for target vessel of index PCI	1-year after randomization
Any revascularization	Any repeat revascularization	1-year after randomization
A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization	A composite of all-cause death/myocardial infarction/stent thrombosis/any revascularization	1-year after randomization
A composite of all-cause death/myocardial infarction	A composite of all-cause death/myocardial infarction	1-year after randomization
A composite of cardiac death/myocardial infarction	A composite of cardiac death/myocardial infarction	1-year after randomization
Cerebrovascular accident	Cerebrovascular accident	1-year after randomization
A composite of all-cause death/myocardial infarction/cerebrovascular accident	A composite of all-cause death/myocardial infarction/cerebrovascular accident	1-year after randomization
A composite of cardiac death/myocardial infarction/cerebrovascular accident	A composite of cardiac death/myocardial infarction/cerebrovascular accident	1-year after randomization
A composite of cardiac death/myocardial infarction/stent thrombosis	A composite of cardiac death/myocardial infarction/stent thrombosis	1-year after randomization
Bleeding by BARC types 3 or 5	Bleeding defined by Bleeding Academic Research Consortium (BARC) types 3 or 5	1-year after randomization
Bleeding by BARC types 2, 3, or 5	Bleeding defined by BARC types 2, 3 or 5	1-year after randomization
Net adverse clinical events	MACE + bleeding by BARC types 3 or 5	1-year after randomization

Collaborators and Investigators

• Sponsor: Samsung Medical Center
• Collaborators: Seoul St. Mary's Hospital; Chonnam National University Hospital; Gachon University Gil Medical Center; Chung-Ang University Hosptial, Chung-Ang University College of Medicine; Gyeongsang National University Hospital; Yeungnam University Hospital; Keimyung University Dongsan Medical Center; Soonchunhyang University Hospital; Sejong General Hospital; Chungnam National University Hospital; Wonju Severance Christian Hospital; Wonkwang University Hospital; Chungbuk National University Hospital; Incheon St.Mary's Hospital; Dankook University; Inje University Ilsan Paik Hospital; Ewha Womans University Seoul Hospital; Mediplex Sejong Hospital; Konkuk University Chungju Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 13, 2020
• Primary Completion (Anticipated): June 30, 2025
• Study Completion (Anticipated): December 31, 2026

Study Registration Dates

• First Submitted: July 8, 2019
• First Submitted That Met QC Criteria: July 8, 2019
• First Posted (Actual): July 10, 2019

Study Record Updates

• Last Update Posted (Actual): April 13, 2023
• Last Update Submitted That Met QC Criteria: April 12, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Percutaneous Coronary Intervention; Complex Coronary Lesion; Dual Antiplatelet Therapy
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Coronary Artery Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Antipyretics; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Aspirin; Clopidogrel; Prasugrel Hydrochloride
• Other Study ID Numbers: ATTEMPT16453143

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No